IsoRay

IsoRay, Inc. is a medical technology company, which engages in the development, manufacture, and sale of isotope-based medical products and devices. The firm focuses on the treatment of cancer and other malignant diseases. Its core product is Cesium-131, a radioisotope for the treatment of malignant tumors. The company was founded by Lance A. Bray in 1983 and is headquartered in Richland, WA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1983 and is headquartered in Seattle, WA.

IsoRay, Inc. (ISR) CEO Lori Woods on Q1 2021 Results - Earnings Call Transcript

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and 6.56%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q3 Loss, Tops Revenue Estimates

Revenue Increased 10% Sequentially  Record Non-Prostate Brachytherapy Revenue Increased 20% Year-Over-Year

Isoray Announces Third Quarter Fiscal 2021 Financial Results

Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, May 13 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce Third Quarter Fiscal 2021 Financial Results on May 13, 2021

RICHLAND, Wash., April 13, 2021 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator, today announced that Donna Fort has been appointed Vice President, Sales and Marketing.

Isoray Announces the Appointment of Donna Fort as Vice President Sales and Marketing

RICHLAND, Wash., March 31, 2021 (GLOBE NEWSWIRE) -- A recently published small prospective series of patients with recurrent head and neck (H&N) cancers treated with surgical resection and Isoray's Cesium-131 brachytherapy found potential benefits that support further research into combination therapy with Cesium-131 brachytherapy and surgical resection.

University Hospitals Cleveland Medical Center Pilot Study Shows Promise for High-Risk Recurrent Head and Neck Cancer Treatment with Cesium-131 and Surgical Resection

The stock price of IsoRay, Inc. (NYSEAMERICAN: ISR) is trading at above 5% pre-market. This is why it happened.

ISR Stock Price Increases Over 5% Pre-Market: Why It Happened

IsoRay is a specialist of brachytherapy using proprietary radioactive seeds based on Cesium-131 to cheaply, safely and effectively treat certain cancers. Its main market is that for certain prostate cancer treatments and that has been affected by the pandemic, but there is a large and growing backlog.

IsoRay Is Branching Out

IsoRay, Inc. (ISR) CEO Lori Woods on Q2 2021 Results - Earnings Call Transcript

Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, February 9, 2021 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce Second Quarter Fiscal 2021 Financial Results on February 9, 2021

IsoRay (ISR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

IsoRay (ISR) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

American Battery Technology Company

Guardion Health Sciences Inc

ObsEva

Safe Bulkers

Zomedica

There's an old saying that 'gaps refill'. And that means that these 7 penny stock Bubbles may be about to burst.

7 Penny Stock Bubbles That Are About to Burst

RICHLAND, Wash., Jan. 07, 2021 (GLOBE NEWSWIRE) --  Isoray, Inc. (NYSE American: ISR), a medical technology company and seed brachytherapy innovator powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at the H.C. Wainwright BioConnect 2021 Conference. The virtual conference will be held January 11-14, 2021.

Isoray to Present at the H.C. Wainwright BioConnect 2021 Conference

Change Healthcare Inc

Aikido Pharma Inc.

Alkido Pharma (NASDAQ: AIKI) shares are trading higher after the company announced it executed a Patent License Agreement for technology that covers the use of psilocybin for cancer applications. AIkido Pharma is engaged in the development of small-molecule anti-cancer therapeutics.

Why Change Healthcare, Isoray And Alkido Are Moving Today

Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World's Premier Radiation Oncology Society Studies Demonstrate Impact of Proprietary Isotope on Prostate and Brain Cancers At World's Premier Radiation Oncology Society 

Isoray's Cesium-131 Spotlighted in Multiple Presentations at ASTRO

IsoRay (ISR) delivered earnings and revenue surprises of 0.00% and -21.32%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q1 Loss, Lags Revenue Estimates

Isoray Announces First Quarter Fiscal 2021 Financial Results

Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Tuesday, November 10, 2020 at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce First Quarter Fiscal 2021 Financial Results on November 10, 2020

RICHLAND, Wash., Oct. 19, 2020 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR) (“Isoray” or the “Company”), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that it intends to offer and sell shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering. All shares of common stock and warrants to purchase common stock will be sold by Isoray. The proposed offering is subject to market and other conditions. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. 

Isoray, Inc. Announces Proposed Underwritten Public Offering

IsoRay, Inc. (ISR) CEO Lori Woods on Q4 2020 Results - Earnings Call Transcript

IsoRay (ISR) delivered earnings and revenue surprises of -100.00% and -17.73%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

IsoRay (ISR) Reports Q4 Loss, Lags Revenue Estimates

Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year Record Full Year Revenue and Gross Profit Full Year Revenue Increased 32% Year-Over-Year

Isoray Announces Fourth Quarter and Full-Year Fiscal Year End 2020 Financial Results

RICHLAND, Wash., Sept.  16, 2020  (GLOBE NEWSWIRE) --   Isoray, Inc.  (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy powering expanding treatment options throughout the body, today announced that Chief Executive Officer Lori Woods will present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit on Wednesday, September 23 at 1:40 p.m. ET. CEO Woods and Chief Financial Officer Jonathan Hunt will also host virtual one-on-one and group meetings with institutional investors during the conference.

Isoray to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit

Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT Conference Call is Thursday, September 17, 2020, at 4:30 p.m. ET/1:30 p.m. PT

Isoray To Announce Fourth Quarter and Fiscal Year End 2020 Financial Results on September 17, 2020

Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection Trial Will Evaluate Use of Pembrolizumab, Known as Keytruda®*, With Cesium-131 and Surgical Resection

News for IsoRay Stock (ISR)